Head-To-Head Contrast: BioNTech (BNTX) versus Its Competitors

BioNTech (NASDAQ:BNTX – Get Free Report) is one of 843 public companies in the “Biotechnology” industry, but how does it weigh in compared to its rivals? We will compare BioNTech to similar businesses based on the strength of its earnings, dividends, analyst recommendations, institutional ownership, risk, profitability and valuation.

Profitability

This table compares BioNTech and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
BioNTech -61.39% -4.51% -3.96%
BioNTech Competitors -12,319.70% -407.93% -30.95%

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for BioNTech and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioNTech 1 5 12 1 2.68
BioNTech Competitors 9931 15324 45730 1605 2.54

BioNTech presently has a consensus target price of $122.27, indicating a potential upside of 43.89%. As a group, “Biotechnology” companies have a potential upside of 134.71%. Given BioNTech’s rivals higher possible upside, analysts plainly believe BioNTech has less favorable growth aspects than its rivals.

Risk & Volatility

BioNTech has a beta of 1.28, meaning that its share price is 28% more volatile than the S&P 500. Comparatively, BioNTech’s rivals have a beta of -1.84, meaning that their average share price is 284% less volatile than the S&P 500.

Insider & Institutional Ownership

15.5% of BioNTech shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 19.2% of BioNTech shares are held by insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares BioNTech and its rivals top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
BioNTech $3.25 billion -$1.29 billion -12.40
BioNTech Competitors $715.39 million $10.31 million -18.32

BioNTech has higher revenue, but lower earnings than its rivals. BioNTech is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Summary

BioNTech beats its rivals on 10 of the 13 factors compared.

BioNTech Company Profile

(Get Free Report)

BioNTech SE is a biotechnology company based in Mainz, Germany. Founded in 2008, it develops medicines and vaccines, with a focus on immunotherapies for cancer and infectious diseases. The company’s research uses technologies including messenger RNA (mRNA), antibodies, and cell-based therapies. Its best-known product is Comirnaty, an mRNA vaccine against COVID-19 developed and commercialized in partnership with Pfizer. BioNTech also has a broad oncology research and development portfolio. BioNTech works with partners to develop and distribute products internationally.

Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.